Ranibizumab is a vascular endothelial growth factor A inhibitor licensed for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia.

A cost-utility model was developed using the pivotal phase III RADIANCE study results. This indicated that the health gains associated with ranibizumab treatment over a patient’s lifetime are higher than those associated with the previous standard of care, verteporfin photodynamic therapy (vPDT), or managing patients through observation.

Ranibizumab treatment was associated with lower lifetime costs than vPDT and is therefore an economically dominant alternative to vPDT for the treatment of myopic CNV in the UK healthcare setting. Ranibizumab treatment is cost effective compared with observation.